Pathology Research International system, the peptide nucleic acid-locked nucleic acid PCR clamp,” Cancer Research, vol. 65, no. 16, pp. 7276–7282, 2005. [25] G. Ellison, E. Donald, G. McWalter et al., “A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples,” Journal of Experimental and Clinical Cancer Research, vol. 29, no. 1, article 132, 2010. [26] S. Park, A. J. Holmes-Tisch, E. Y. Cho et al., “Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 4, no. 7, pp. 809–815, 2009. [27] K. Schmid, N. Oehl, F. Wrba, R. Pirker, C. Pirker, and M. Filipits, “EGFR/KRAS/BRAF mutations in primary lung ade- nocarcinomas and corresponding locoregional lymph node metastases,” Clinical Cancer Research, vol. 15, no. 14, pp. 4554– 4560, 2009. [28] S. X. Jiang, K. Yamashita, M. Yamamoto et al., “EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired geﬁtinib resistance,” International Journal of Cancer, vol. 123, no. 11, pp. 2480–2486, 2008. [29] A. Kitamura, W. Hosoda, E. Sasaki, T. Mitsudomi, and Y. Yatabe, “Immunohistochemical detection of EGFR mutation using mutation-speciﬁc antibodies in lung cancer,” Clinical Cancer Research, vol. 16, no. 13, pp. 3349–3355, 2010. [30] A. Kawahara, C. Yamamoto, K. Nakashima et al., “Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-speciﬁc antibodies for immunohisto- chemical analysis,” Clinical Cancer Research, vol. 16, no. 12, pp. 3163–3170, 2010. [31] Y. Kato, N. Peled, M. W. Wynes et al., “Novel epidermal growth factor receptor mutation-speciﬁc antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations,” Journal of Thoracic Oncology, vol. 5, no. 10, pp. 1551–1558, 2010. [32] W. Pao, V. A. Miller, K. A. Politi et al., “Acquired resistance of lung adenocarcinomas to geﬁtinib or erlotinib is associated with a second mutation in the EGFR kinase domain,” PLoS Medicine, vol. 2, no. 3, p. e73, 2005. [33] T. Kosaka, Y. Yatabe, H. Endoh et al., “Analysis of epidermal growth factor receptor gene mutation in patients with non- small cell lung cancer and acquired resistance to geﬁtinib,” Clinical Cancer Research, vol. 12, no. 19, pp. 5764–5769, 2006. [34] J. A. Engelman, K. Zejnullahu, T. Mitsudomi et al., “MET ampliﬁcation leads to geﬁtinib resistance in lung cancer by activating ERBB3 signaling,” Science, vol. 316, no. 5827, pp. 1039–1043, 2007. [35] J. Bean, C. Brennan, J. Y. Shih et al., “MET ampliﬁcation occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to geﬁtinib or erlotinib,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 52, pp. 20932–20937, 2007. [36] A. B. Turke, K. Zejnullahu, Y. L. Wu et al., “Preexistence and clonal selection of MET ampliﬁcation in EGFR mutant NSCLC,” Cancer Cell, vol. 17, no. 1, pp. 77–88, 2010. [37] S. Maheswaran, L. V. Sequist, S. Nagrath et al., “Detection of mutations in EGFR in circulating lung-cancer cells,” The New England Journal of Medicine, vol. 359, no. 4, pp. 366–377, 2008. [38] Z. Yao, S. Fenoglio, D. C. Gao et al., “TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 35, pp. 15535–15540, 2010. 7 [39] K. E. Ware, M. E. Marshall, L. R. Heasley et al., “Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression,” PloS ONE, vol. 5, no. 11, Article ID e14117, 2010. [40] C. Yamamoto, Y. Basaki, A. Kawahara et al., “Loss of PTEN expression by blocking nuclear translocation of EGR1 in geﬁtinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations,” Cancer Research, vol. 70, no. 21, pp. 8715–8725, 2010. [41] W. Zhou, D. Ercan, L. Chen et al., “Novel mutant-selective EGFR kinase inhibitors against EGFR T790M,” Nature, vol. 462, no. 7276, pp. 1070–1074, 2009. [42] D. Matsubara, S. Ishikawa, S. Oguni, H. Aburatani, M. Fukayama, and T. Niki, “Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells,” Journal of Thoracic Oncology, vol. 5, no. 9, pp. 1317–1324, 2010. [43] C. Mao, L. X. Qiu, R. Y. Liao et al., “KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies,” Lung Cancer, vol. 69, no. 3, pp. 272–278, 2010. [44] R. K. Thomas, A. C. Baker, R. M. Debiasi et al., “High- throughput oncogene mutation proﬁling in human cancer,” Nature Genetics, vol. 39, no. 3, pp. 347–351, 2007. [45] S. P. D’Angelo, B. Park, C. G. Azzoli et al., “Reﬂex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center,” Journal of Thoracic and Cardiovascular Surgery, vol. 141, no. 2, pp. 476–480, 2011. [46] L. Ding, G. Getz, D. A. Wheeler et al., “Somatic mutations aﬀect key pathways in lung adenocarcinoma,” Nature, vol. 455, no. 7216, pp. 1069–1075, 2008. [47] H. Shigematsu, T. Takahashi, M. Nomura et al., “Somatic mutations of the HER2 kinase domain in lung adenocarcino- mas,” Cancer Research, vol. 65, no. 5, pp. 1642–1646, 2005. [48] M. S. Brose, P. Volpe, M. Feldman et al., “BRAF and RAS mutations in human lung cancer and melanoma,” Cancer Research, vol. 62, no. 23, pp. 6997–7000, 2002. [49] Y. Samuels, Z. Wang, A. Bardelli et al., “High frequency of mutations of the PIK3CA gene in human cancers,” Science, vol. 304, no. 5670, p. 554, 2004. [50] H. Yamamoto, H. Shigematsu, M. Nomura et al., “PIK3CA mutations and copy number gains in human lung cancers,” Cancer Research, vol. 68, no. 17, pp. 6913–6921, 2008. [51] D. Dias-Santagata, S. Akhavanfard, S. S. David et al., “Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine,” EMBO Molecular Medicine, vol. 2, no. 5, pp. 146–158, 2010. [52] S. H. I. Ou and J. A. Zell, “Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies,” Journal of Thoracic Oncology, vol. 4, no. 10, pp. 1202–1211, 2009. [53] G. E. Stoica, A. Kuo, A. Aigner et al., “Identiﬁcation of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin,” Journal of Biological Chemistry, vol. 276, no. 20, pp. 16772–16779, 2001. [54] H. H. Lee, A. Norris, J. B. Weiss, and M. Frasch, “Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers,” Nature, vol. 425, no. 6957, pp. 507– 512, 2003. [55] C. A. Griﬃn, A. L. Hawkins, C. Dvorak, C. Henkle, T. Ellingham, and E. J. Perlman, “Recurrent involvement of 2p23 in inﬂammatory myoﬁbroblastic tumors,” Cancer Research, vol. 59, no. 12, pp. 2776–2780, 1999.